Form 4: TuHURA Biosciences CEO Acquires 1,065,990 Stock Options
SEC Form 4 Filing
TuHURA Biosciences CEO, James A. Bianco, was granted 1,065,990 stock options on November 12, 2024, which vest over three years.
Summary
- James A. Bianco, the CEO of TuHURA Biosciences, Inc., acquired 1,065,990 stock options on November 12, 2024.
- The options have an exercise price of $4.94.
- The options vest in three equal tranches, with one-third becoming exercisable on each of the first, second, and third anniversaries of the grant date.
- The options expire on November 12, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The grant of stock options to the CEO aligns his interests with those of shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The stock options will vest over the next three years, incentivizing the CEO to increase shareholder value.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of three years is also typical, encouraging long-term performance.
- The exercise price of $4.94 is specific to TuHURA Biosciences and its current valuation.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the CEO's interests with their own.
- The vesting schedule encourages long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 11/12/2024 | Date of the stock option grant. |
| 11/14/2024 | Date the form was signed. |
| 11/12/2025 | First vesting date for one-third of the options. |
| 11/12/2026 | Second vesting date for one-third of the options. |
| 11/12/2027 | Third vesting date for one-third of the options. |
| 11/12/2034 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, TuHURA Biosciences, HURA, James A. Bianco
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.